Gland Pharma Ltd

GLAND

Watchlist

AI Mode

‌

Market Cap

₹ 27,513 Cr

P/E

34.81

‌

Investment Checklist

How to read checklist?

Performance

UNDER PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Gland Pharma Limited is a leading global player in the generic injectables market, with a robust manufacturing and R&D capability. The company operates on a B2B model, serving over 60 countries including the U.S., Europe, and India.

The company reported a 6% YoY growth in Q2 FY26 revenue driven by strong U.S. market performance, new product launches, and expansion in the CDMO sector.

Gland Pharma is strategically expanding its capacity, focusing on high-growth sectors such as GLP-1 manufacturing and complex injectables, aligning with the global trends in specialty pharma and biologics.

Recent strategic acquisitions, including Cenexi, enhance Gland Pharma's capabilities in biotechnology and biologics, supporting its transformation into an innovation-driven CDMO and specialty injectables leader.

The company's focus on R&D is evident with significant investment aimed at developing complex injectables and innovative delivery systems, strengthening its competitive edge in the high-value pharmaceuticals market.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

27,513 Cr

Volatility

Low Risk

P/E Ratio

34.8

Industry P/E

43.8

PEG Ratio

1.5

P/B Ratio

2.9

52W High

2,130.00

52W Low

1,200.00

Sales CAGR

-0.85%

-2.20%

9.35%

10Y

—

Profit CAGR

-9.57%

-3.49%

7.11%

10Y

—

ROE

TTM

8.27%

10.89%

12.87%

10Y

14.56%

ROCE

TTM

12.46%

14.62%

17.17%

10Y

18.99%

Technicals

‌

Forecasts

No. of Analysts

21

1Y Price Target

2083.00 ▲ 25.28%

Q3 EPS Estimate

Q3 Revenue Estimate

Unlock Premium Features

Price, EPS and Revenue Projections

Strong SellSellHoldBuyStrong Buy

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

updated on

Dec 03, 2025

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AJANTPHARM	2638.15	32,971 Cr	33.86	7.64	1.06	22.56	27.85	17.17
GLAND	1669.90	27,513 Cr	34.81	2.88	1.08	8.27	12.46	6.70
ERIS	1588.20	21,607 Cr	51.97	6.99	0.46	13.45	14.38	6.27
SAILIFE	909.85	19,138 Cr	66.80	8.43	0.00	12.62	16.34	8.60
CAPLIPOINT	1957.00	14,864 Cr	25.24	4.70	0.31	18.64	23.29	17.02
RUBICON	634.55	10,481 Cr	78.34	10.03	0.00	41.49	34.93	8.82
MARKSANS	190.80	8,646 Cr	24.59	3.22	0.42	13.08	16.13	10.26

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	1,209	1,373	1,545	1,537	1,402	1,406	1,384	1,425	1,506	1,487
Expenses	915	1,049	1,189	1,179	1,137	1,109	1,024	1,077	1,138	1,173
Operating Profit	294	324	356	359	264	297	360	348	368	314
OPM %	24.32	23.60	23.06	23.33	18.86	21.13	26.01	24.39	24.43	21.11
Other Income	38	53	37	42	51	60	58	44	58	84
Interest	4.92	6.05	5.28	9.96	5.62	6.11	23	7.45	12	7.82
Depreciation	65	81	105	93	92	94	96	96	101	106
Profit Before Tax	261	290	283	298	218	257	299	288	313	284
Tax %	25.71	33.05	32.24	35.48	34.13	36.32	31.61	35.30	31.10	35.30
Net Profit	194	194	192	192	144	164	205	187	215	184
EPS in Rs	11.78	11.78	11.65	11.68	8.73	9.93	12.42	11.32	13.08	11.15

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	2,633	3,463	4,401	3,625	5,665	5,617	5,617
Expenses	1,678	2,161	2,891	2,600	4,332	4,348	4,348
Operating Profit	955	1,302	1,510	1,025	1,333	1,269	1,269
OPM %	36.28	37.61	34.32	28.27	23.53	22.59	22.59
Other Income	139	135	224	184	170	214	214
Interest	7.18	3.41	5.24	7.45	26	42	42
Depreciation	95	99	110	147	345	378	378
Profit Before Tax	993	1,335	1,619	1,055	1,133	1,063	1,063
Tax %	22.16	25.31	25.14	25.94	31.79	34.27	34.27
Net Profit	773	997	1,212	781	772	699	699
EPS in Rs	—	62.83	73.46	47.41	46.87	42.40	47.97
Dividend Payout %	0.00	0.00	0.00	0.00	42.65	42.45	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	15	16	16	16	16	16
Reserves	3,631	5,887	7,141	7,942	8,707	9,134
Borrowings	4.07	5.00	4.74	4.45	372	314
Other Liabilities	436	588	671	814	1,565	1,760
Total Liabilities	4,086	6,496	7,834	8,778	10,661	11,225
Fixed Assets	968	954	1,502	1,571	3,947	4,147
CWIP	188	338	191	177	238	151
Investments	0.00	0.00	155	0.00	0.00	0.00
Other Assets	2,929	5,204	5,986	7,030	6,477	6,927
Total Assets	4,086	6,496	7,834	8,778	10,661	11,225

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	701	605	791	364	997	915
Cash from Investing Activity	-766	-1,524	-1,003	1,208	-1,757	1,705
Cash from Financing Activity	-6.87	1,238	35	15	-799	-433
Net Cash Flow	-72	319	-177	1,587	-1,560	2,186

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	57.86%	57.86%	57.86%	57.86%	57.86%	57.86%	51.83%	51.83%	51.83%	51.83%	51.83%	51.83%
FIIs	4.67%	4.33%	2.80%	4.91%	4.04%	3.59%	6.88%	4.47%	5.04%	6.90%	7.39%	7.91%
DIIs	23.14%	23.23%	23.38%	22.45%	24.17%	25.23%	32.83%	35.37%	34.80%	33.27%	32.85%	32.64%
Public	14.33%	14.58%	15.96%	14.78%	13.93%	13.32%	8.45%	8.32%	8.33%	7.99%	7.93%	7.63%
Total Shareholders	1,48,469	1,50,578	1,81,747	1,61,627	1,36,021	1,22,375	1,22,665	1,22,358	1,21,075	1,13,788	1,10,671	97,151

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Nov 25, 2025	Lakshmi narayana pulaparthi	Insider - Designated Person	Disposal	1,802.82	0.05 Cr	300	—
Sep 29, 2025	A jayatheerth	Insider - Designated Person	Disposal	1,988.90	0.04 Cr	191	—
Sep 29, 2025	A jayatheerth	Insider - Designated Person	Disposal	2,038.00	0.07 Cr	325	—
Mar 21, 2025	Vanguard emerging markets sto...	Bulk	Buy	1,588.69	133.22 Cr	8,38,556	0.50
Mar 21, 2025	Vanguard total international ...	Bulk	Buy	1,588.69	161.45 Cr	10,16,219	0.61
Feb 26, 2025	S sreenivasa rao	Insider - Designated Person	Acquisition	542.00	0.15 Cr	2,800	—
Jun 28, 2024	Bh lenin kumar raja	Insider - Designated Person	Disposal	1,807.86	0.25 Cr	1,400	—
Jun 28, 2024	Rong wu	Insider - Designated Person	Disposal	1,820.25	1.13 Cr	6,182	—
Jun 28, 2024	P b ravindra varma	Insider - Designated Person	Disposal	1,810.00	0.35 Cr	1,950	—
Jun 28, 2024	Srinivasa rao s	Insider - Designated Person	Disposal	1,812.28	0.35 Cr	1,950	—

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Investor Meet

5 days ago

Schedule of Analyst/Investor Meetings

Gland Pharma Limited has announced a schedule for Analyst/Institutional Investor meetings on December 16, 2025.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q1 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q3 FY24

Showing 1 - 8 of 21

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

The company reported a 6% YoY growth in Q2 FY26 revenue driven by strong U.S. market performance, new product launches, and expansion in the CDMO sector.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

27,513 Cr

Volatility

Low Risk

P/E Ratio

34.8

Industry P/E

43.8

PEG Ratio

1.5

P/B Ratio

2.9

52W High

2,130.00

52W Low

1,200.00

Sales CAGR

-0.85%

-2.20%

9.35%

10Y

—

Profit CAGR

-9.57%

-3.49%

7.11%

10Y

—

ROE

TTM

8.27%

10.89%

12.87%

10Y

14.56%

ROCE

TTM

12.46%

14.62%

17.17%

10Y

18.99%

Gland Pharma Ltd

Gland Pharma Ltd

GLAND

AI Mode

Investment Checklist

Investment Checklist

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Technicals

Forecasts

21

2083.00 ▲ 25.28%

Upgrade

Upgrade

Upgrade

Upgrade

Unlock Premium Features

Upgrade

Buy

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Projection

Unlock Premium Features

Upgrade

Actions

Announcements

Documents

AI Mode

AI Mode

Technicals

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Peers

Price Chart Comparison

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Announcements

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Investment Checklist